Purine nucleoside phosphorylase gene therapy - PNP Therapeutics

Drug Profile

Purine nucleoside phosphorylase gene therapy - PNP Therapeutics

Alternative Names: Ad/PNP; Adenovirus/PNP; Gedeptin

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Southern Research Institute; University of Alabama
  • Developer PNP Therapeutics
  • Class Gene therapies
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pharyngeal neoplasms; Orofacial cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase Unknown Pharyngeal neoplasms
  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (Intratumoural, Injection)
  • 26 Apr 2016 Phase-I development is ongoing in USA
  • 16 Jun 2015 Purine nucleoside phosphorylase gene therapy - PNP Therapeutics is available for licensing as of 16 Jun 2015. http://www.pnptherapeutics.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top